237 related articles for article (PubMed ID: 28692107)
1. Whole blood ristocetin-activated platelet impedance aggregometry (Multiplate) for the rapid detection of Von Willebrand disease.
Schmidt DE; Bruzelius M; Majeed A; Odeberg J; Holmström M; Ågren A
Thromb Haemost; 2017 Jul; 117(8):1528-1533. PubMed ID: 28692107
[TBL] [Abstract][Full Text] [Related]
2. Whole blood ristocetin-induced platelet impedance aggregometry does not reflect clinical severity in patients with type 1 von Willebrand disease.
Nakajima Y; Nogami K; Yada K; Ogiwara K; Furukawa S; Shimonishi N; Shima M
Haemophilia; 2019 May; 25(3):e174-e179. PubMed ID: 30866149
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children.
Frontroth JP; Hepner M; Sciuccati G; Feliú Torres A; Pieroni G; Bonduel M
Thromb Haemost; 2010 Dec; 104(6):1158-65. PubMed ID: 20941465
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination.
Stufano F; Baronciani L; Pagliari MT; Franchi F; Cozzi G; Garcia-Oya I; Bucciarelli P; Boscarino M; Peyvandi F
J Thromb Haemost; 2015 Oct; 13(10):1806-14. PubMed ID: 26206100
[TBL] [Abstract][Full Text] [Related]
5. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.
Flood VH; Gill JC; Morateck PA; Christopherson PA; Friedman KD; Haberichter SL; Hoffmann RG; Montgomery RR
Blood; 2011 Feb; 117(6):e67-74. PubMed ID: 21148813
[TBL] [Abstract][Full Text] [Related]
6. Ristocetin-Induced Platelet Aggregation (RIPA) and RIPA Mixing Studies.
Frontroth JP; Favaloro EJ
Methods Mol Biol; 2017; 1646():473-494. PubMed ID: 28804849
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
Akin M; Karapinar DY; Balkan C; Ay Y; Kavakli K
Clin Appl Thromb Hemost; 2011 Oct; 17(5):441-8. PubMed ID: 20460340
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system.
Ågren A; Holmström M; Schmidt DE; Hosokawa K; Blombäck M; Hjemdahl P
Thromb Haemost; 2017 Jan; 117(1):75-85. PubMed ID: 27761577
[TBL] [Abstract][Full Text] [Related]
9. Technological advances in diagnostic testing for von Willebrand disease: new approaches and challenges.
Hayward CP; Moffat KA; Graf L
Int J Lab Hematol; 2014 Jun; 36(3):334-40. PubMed ID: 24750680
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive re-evaluation of historical von Willebrand disease diagnosis in association with whole blood platelet aggregation and function.
Nummi V; Lassila R; Joutsi-Korhonen L; Armstrong E; Szanto T
Int J Lab Hematol; 2018 Jun; 40(3):304-311. PubMed ID: 29427305
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels.
Lehmann M; Ashworth K; Manco-Johnson M; Di Paola J; Neeves KB; Ng CJ
J Thromb Haemost; 2018 Jan; 16(1):104-115. PubMed ID: 29064615
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Value of Measuring Platelet Von Willebrand Factor in Von Willebrand Disease.
Casonato A; Cattini MG; Daidone V; Pontara E; Bertomoro A; Prandoni P
PLoS One; 2016; 11(8):e0161310. PubMed ID: 27532107
[TBL] [Abstract][Full Text] [Related]
13. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
Giannini S; Mezzasoma AM; Leone M; Gresele P
Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease.
Favaloro EJ
Thromb Haemost; 2010 Nov; 104(5):1009-21. PubMed ID: 20806123
[TBL] [Abstract][Full Text] [Related]
15. Advances in the diagnosis and treatment of Von Willebrand disease.
Sharma R; Flood VH
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):379-384. PubMed ID: 29222282
[TBL] [Abstract][Full Text] [Related]
16. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
17. Laboratory Testing for von Willebrand Disease: The Past, Present, and Future State of Play for von Willebrand Factor Assays that Measure Platelet Binding Activity, with or without Ristocetin.
Just S
Semin Thromb Hemost; 2017 Feb; 43(1):75-91. PubMed ID: 27978590
[TBL] [Abstract][Full Text] [Related]
18. The genetic basis of von Willebrand disease.
Goodeve AC
Blood Rev; 2010 May; 24(3):123-34. PubMed ID: 20409624
[TBL] [Abstract][Full Text] [Related]
19. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
[TBL] [Abstract][Full Text] [Related]
20. Abnormalities of factor VIII and platelet aggregation--use of ristocetin in diagnosing the von Willebrand syndrome.
Weiss HJ
Blood; 1975 Mar; 45(3):403-12. PubMed ID: 1078779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]